Inosine Acedoben Dimepranol promotes an early and sustained increase in the natural killer cell component of circulating lymphocytes: A clinical trial supporting anti-viral indications
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2017 |
|---|---|
| Erschienen: |
2017 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:42 |
|---|---|
| Enthalten in: |
International immunopharmacology - 42(2017), Seite 108-114 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Rumel Ahmed, S [VerfasserIn] |
|---|
| Links: |
|---|
| BKL: |
|---|
| doi: |
10.1016/j.intimp.2016.11.023 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
OLC1989824617 |
|---|
| LEADER | 01000caa a2200265 4500 | ||
|---|---|---|---|
| 001 | OLC1989824617 | ||
| 003 | DE-627 | ||
| 005 | 20230515132356.0 | ||
| 007 | tu | ||
| 008 | 170207s2017 xx ||||| 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.intimp.2016.11.023 |2 doi | |
| 028 | 5 | 2 | |a PQ20170301 |
| 035 | |a (DE-627)OLC1989824617 | ||
| 035 | |a (DE-599)GBVOLC1989824617 | ||
| 035 | |a (PRQ)c691-ae14f9862a4d656ba3428940ea63d0ce2e4e1074ad5db92f9d6d6d15ed1acbec0 | ||
| 035 | |a (KEY)0451235920170000042000000108inosineacedobendimepranolpromotesanearlyandsustain | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q DNB |
| 084 | |a PHARM |2 fid | ||
| 084 | |a 44.00 |2 bkl | ||
| 100 | 1 | |a Rumel Ahmed, S |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Inosine Acedoben Dimepranol promotes an early and sustained increase in the natural killer cell component of circulating lymphocytes: A clinical trial supporting anti-viral indications |
| 264 | 1 | |c 2017 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 700 | 1 | |a Newman, Amy S |4 oth | |
| 700 | 1 | |a O'Daly, James |4 oth | |
| 700 | 1 | |a Duffy, Sean |4 oth | |
| 700 | 1 | |a Grafton, Gillian |4 oth | |
| 700 | 1 | |a Brady, Catherine A |4 oth | |
| 700 | 1 | |a John Curnow, S |4 oth | |
| 700 | 1 | |a Barnes, Nicholas M |4 oth | |
| 700 | 1 | |a Gordon, John |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t International immunopharmacology |d Amsterdam [u.a.] : Elsevier, 2001 |g 42(2017), Seite 108-114 |w (DE-627)327645016 |w (DE-600)2043785-7 |w (DE-576)094399468 |x 1567-5769 |7 nnns |
| 773 | 1 | 8 | |g volume:42 |g year:2017 |g pages:108-114 |
| 856 | 4 | 1 | |u http://dx.doi.org/10.1016/j.intimp.2016.11.023 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_OLC | ||
| 912 | |a FID-PHARM | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a SSG-OLC-DE-84 | ||
| 912 | |a SSG-OPC-PHA | ||
| 912 | |a GBV_ILN_4219 | ||
| 936 | b | k | |a 44.00 |q AVZ |
| 951 | |a AR | ||
| 952 | |d 42 |j 2017 |h 108-114 | ||